SALT LAKE CITY, Sept. 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of Economic Opportunity, as part of the latest World Trade Center (WTC) Utah trade mission to South Korea and Japan from September 24-October 5.Co-Dx will join the delegation for life scie ...

SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. The results of the analysis show that the test should retain full reactivity against mpox strains circulating ove ...

财务数据和关键指标变化 - 第二季度总收入增加至2.7百万美元,而上年同期为0.2百万美元 [31] - 第二季度毛利增加至2.4百万美元,而上年同期为负0.3百万美元 [31] - 第二季度税前亏损为7.7百万美元,而上年同期为11.2百万美元 [33] - 第二季度净亏损为7.6百万美元,每股摊薄亏损0.25美元,而上年同期为8.9百万美元,每股摊薄亏损0.31美元 [33] - 第二季度调整后EBITDA亏损为5.9百万美元,而上年同期为9.6百万美元 [33] - 公司期末现金、现金等价物和可流动投资证券为44.9百万美元 [34] 各条业务线数据和关键指标变化 - 第二季度产品收入为0.2百万美元,授权收入为2.5百万美元 [31] - 公司正在开发结核病、呼吸道多重检测、HPV和链球菌检测等测试 [18][21][24][25] - 公司正在为结核病检测进行临床试验,预计在今年年底前在南非和印度开展 [18][19] - 公司认为全球结核病检测市场在未来4年内可能达到36亿美元 [20] 各个市场数据和关键指标变化 - 公司的矢量控制业务在美国继续扩张,已覆盖15个州 [26] - 公司的产品已销往全球50多个国家,在国内外市场都有广泛的分销商网络 [44] 公司战略和发展方向及行业竞争 - 公司提交了首个510(k)申请,用于Co-Dx PCR Pro仪器和Co-Dx PCR COVID-19检测试剂盒的非处方(OTC)使用 [9][12][13] - 获得OTC批准后,公司计划将产品销售给消费者和企业,以及针对高量使用的医疗机构 [14] - 公司参加了FIME和ADLM两个重要行业展会,展示了Co-Dx PCR平台 [15][16][17] - 公司正在不断提升Co-Dx PCR平台的性能和功能,以满足市场需求 [21][22][23] - 公司正在探索利用现有技术检测禽流感H5N1病毒的可能性 [27] 管理层对经营环境和未来前景的评论 - 管理层对公司在2024年上半年取得的进展表示满意,并对剩余时间的执行目标充满信心 [8][11] - 管理层认为公司处于强大的现金头寸,将继续专注于提高运营效率 [34][35] - 管理层对Co-Dx PCR平台的市场前景和测试管线感到乐观 [28][29] 其他重要信息 - 公司的Co-Primers技术可以显著降低假阳性率,提高诊断结果的可信度 [28] - 公司的仪器体积小、内部制造能力强、财务管理良好,以及获得的赠款支持,为商业化奠定了基础 [29] 问答环节重要的提问和回答 问题1 **Jade Montgomery 提问** 是否已收到FDA对510(k)申请的任何反馈或指导 [37][38][39][40] **Dwight Egan 回答** 公司与FDA保持定期沟通,对FDA的反馈到目前为止感到满意,但不能对监管决定做出评论 [38][40] 问题2 **Jade Montgomery 提问** 两个行业展会是否已经有潜在客户表示强烈购买意向 [41][42] **Dwight Egan 回答** 公司一直与潜在客户就产品优势和进展进行建设性对话,但在获得FDA批准之前不允许销售产品 [42][44]

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this company would post a loss of $0.21 per share when it actually produced a loss of $0.31, delivering a surprise of -47.62%.Over the last four quarters, the company has su ...

财务表现 - 公司在2024年6月30日三个月内实现收入2,656,840美元，较2023年同期增长[101] - 公司2024年上半年实现收入3,124,694美元，较2023年同期增长[109] 政府补助 - 公司获得2,495,738美元的政府补助收入[101] - 公司获得2,710,847美元的政府补助收入[109] 运营费用 - 公司运营费用下降至10,124,654美元，较2023年同期下降[103] - 公司运营费用下降至20,617,390美元，较2023年同期下降[111] 销售及市场费用 - 销售及市场费用下降至1,041,243美元，较2023年同期下降[104] 研发费用 - 研发费用下降至5,612,691美元，较2023年同期下降[106] - 研发费用增加至11,292,369美元，较2023年同期增长[114] 净亏损 - 公司实现净亏损7,599,318美元，较2023年同期亏损收窄[108] - 实现了6个月内净亏损1691.1361万美元，较上年同期增加[116] 现金流 - 拥有1385.8866万美元现金及现金等价物，另有3102.0811万美元可随时变现的投资证券[117] - 6个月内经营活动净现金流出1369.4532万美元，较上年同期增加[118] - 6个月内投资活动净现金流入1263.652万美元，主要来自投资证券到期[119] - 6个月内融资活动净现金流出为0，较上年同期减少[120] 未来展望 - 公司相信现有资本资源和未来销售产生的现金足以满足未来12个月的预计运营需求[122]

财务表现 - 收入为270万美元，较上年同期增长1350%，主要由于公司获得的各种补助金项目达成里程碑[2] - 经营费用为1010万美元，较上年同期下降13.7%，主要由于股份支付费用、坏账准备和临床试验费用下降[2] - 经营亏损770万美元，较上年同期的1200万美元亏损有所收窄[2] - 净亏损760万美元，较上年同期的890万美元亏损有所收窄，每股摊薄亏损0.25美元，上年同期为0.31美元[2,14] - 调整后EBITDA亏损590万美元，较上年同期的960万美元亏损有所收窄[15] 现金流和财务状况 - 截至2024年6月30日，现金及现金等价物和可供出售金融资产合计44.9百万美元[2] 产品和技术发展 - 向FDA提交了Co-Dx PCR Pro平台和Co-Dx PCR COVID-19检测试剂盒的首个510(k)申请,用于非处方(OTC)使用[3] - 在南盐湖市建立了新的生产设施,用于生产专利的Co-Primers寡核苷酸、Co-Dx PCR Pro仪器和新Co-Dx PCR平台的检测杯[3] - 将Co-Dx向量控制技术扩展到内华达州,包括Vector Smart PCR检测用于蚊虫池的环境监测[3]

SALT LAKE CITY, July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL.Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-c ...

SALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will inc ...

SALT LAKE CITY, July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools f ...

SALT LAKE CITY, June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relat ...